Xencor Gets CD20xCD3 Bispecific Back From J&J

Still Partnered On Two Antibodies

 
• By Joseph Haas
Return
J&J decided to return bispecific antibody plamotamab to Xencor • Source: Shutterstock

More from Deals

More from Business